|
KMID : 0043320120350111855
|
|
Archives of Pharmacal Research
2012 Volume.35 No. 11 p.1855 ~ p.1859
|
|
|
Recent updates on the development of ganetespib as a Hsp90 inhibitor
|
|
Choi Hyun-Kyung
Lee Kyeong
|
|
|
Abstract
|
|
|
|
Heat shock protein 90 (Hsp90) plays a critical role in the maintenance of multiple oncogenic pathways and is a required protein for folding and stability of many oncoproteins that are related to the growth, proliferation, and survival of many kinds of cancers. Ganetespib (STA-9090) is a potent, synthetic, small molecule inhibitor of Hsp90, and its binding to Hsp90 is known to result in the degradation of its client proteins and subsequent death of cancer cells. This article provides a review of ganetespib as one of the leading Hsp90 inhibitors, which is under investigation in a broad range of clinical stages for the treatment of cancer.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|